ZEB1 and neoplasm: Immunohistochemical analyses revealed distinct tumor microenvironment features in DPP-4i users, including increased Zeb1+ tumor cells, reduced CD3+ and CD8+ T cell infiltration, and fewer tertiary lymphoid structures (p < 0.001).